Advancing drug discovery and therapeutic programs with physiologically relevant human iPSC-derived cellular systems

Abstract: Human cell types differentiated from induced pluripotent stem cells (iPSCs) offer an attractive source of cellular material as in vitro systems for drug discovery, and as platforms for cell therapy development. The human origin and the biological relevance of iPSC-derived cells are key elements for modeling human biology in a dish, which is otherwise difficult to explore using conventional cell lines, primary cells, or animal models. Our approach is to generate iPSC-derived cell types with high quality, purity, and unlimited quantities, design relevant assays with cells derived from apparently healthy donors, and develop disease models using environmental stimuli or disease-specific, patient-derived cells.

In this presentation, we will discuss recent advances in iPSC-based technology. iPSC-derived cardiomyocytes, hepatocytes, and neurons will be used to provide examples of their utility in early detection of drug toxicity and in disease modeling. In the regenerative medicine space, we are actively manufacturing cGMP HLA “superdonor” iPSC lines for universal utility, and will provide an overview of our progress in developing iPSC-derived therapies across internal cell therapy programs.